NantHealth and NantOmics Present Four Research Papers Demonstrating Advancements in Cancer Diagnostics with NantHealth’s GPS Cancer® and Liquid GPS™

by Jen Hodson | Oct 29, 2018 | Press Releases

NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer  MUNICH and CULVER CITY, CA – (October 29, 2018) — Significant developments in cancer research were presented by NantHealth (NASDAQ: NH)...

Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors

by Jen Hodson | Aug 27, 2018 | Press Releases

Clinical Trial Tests Personalized Treatments in Push to Improve Pediatric Cancer Survival UCSF Benioff Children’s Hospitals are harnessing next-generation genomic technology to develop individualized drug cocktails in a new trial for children with a type of malignant...

Using the Technology that Powers GPS Cancer ®, Scientists have Developed Fresh Insights into the Driving Mechanisms of a Rare Skin Cancer

by Jen Hodson | Aug 27, 2018 | Press Releases

Peer-reviewed research utilizing NantOmics technology gives scientists fresh insights into driving mechanisms behind a form of rare skin cancer. August 27,2018 – CULVER CITY, Calif  — New, peer-reviewed research utilizing NantOmics technology, which powers...

POC FOR CYTOKINES

by Jen Hodson | Jun 12, 2018 | Press Releases

7:02 pm MST |  Jun 8, 2018  |  BioCentury  |  Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior Writer Download Article...

NantHealth and NantOmics to Present Patterns of Immune Checkpoint molecules in relation to pd-l1 expression at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 4, 2018 | Press Releases

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...

NantHealth and NantOmics to Present Data on Three-fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 4, 2018 | Press Releases

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...